Abstract: The present invention relates to methods for diagnosing or predicting responsiveness to treatment, such as Alefacept, by determining the presence of a nucleotide at one or more polymorphic sites within a haplotype marker. The present invention identifies multiple haplotypes that are associated with response to Alefacept. The haplotype markers identified by the present invention and methods of the invention can be particularly useful for diagnosing or predicting susceptibility to skin diseases, such as Psoriasis.

Abstract: Haplotypes in the NTRK1 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these NTRK1 haplotypes are disclosed.

Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Abstract: Haplotypes in the CHRNA9 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these CHRNA9 haplotypes are disclosed.

Abstract: Haplotypes in the NTRK2 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these NTRK2 haplotypes are disclosed.

Abstract: Haplotypes in the APOA4 gene associated with progression of Alzheimer's Disease are disclosed. Compositions and methods for detecting these APOA4 haplotypes are disclosed.

Abstract: A method of ensuring the security of data from a medical test includes providing the patient with a medical data card issued by a secure information provider, and having a unique patient identification number (PID), a public key encryption private key, and public key encryption public key (Key 2). The method further includes a first test request card having an encrypted identification of the patient and the test, a health care provider code, Key 2, and the test type that accompanies the patient's test specimen to the secure information provider, a second test request card bearing an encryption of the PID and the test type to forward with the patient's specimen to a testing laboratory; a first test results card bearing an encryption of the PID and the results; and a second test results card that may be read in conjunction with the patient's medical data card.

Abstract: Methods for detecting variant genes having a polymorphism associated with reduced metabolism of a substrate selected from the group consisting of a CYP3A4 substrate, a CYP3A5 substrate and a GSTM1 substrate in an individual are disclosed. The methods are genotyping methods to identify specific polymorphisms which have been found to be associated with reduced metabolism of chemotherapeutic agents, such as cyclophosphamide and BCNU. Also disclosed are novel polymorphic nucleic acid molecules useful in the methods of the invention.

Abstract: Methods, computer program(s) and database(s) to analyze and make use of gene haplotype information. These include methods, program, and database to find and measure the frequency of haplotypes in the general population; methods, program, and database to find correlation's between an individual's haplotypes or genotypes and a clinical outcome; methods, program, and database to predict an individual's haplotypes from the individual's genotype for a gene; and methods, program, and database to predict an individual's clinical response to a treatment based on the individual's genotype or haplotype.

Abstract: A novel polymorphic site in the 5? leader cistron of the ?2-adrenergic receptor (?2AR) gene is disclosed. The polymorphisms present at this site result in different levels of inhibition of translation of ?2AR mRNA. Compositions and methods for genotyping this polymorphic site as disclosed. In addition, methods for using this genotype information are disclosed, including predicting genetic predisposition to a disease modified by ?2AR expression and predicting a patient's bronchodilating response to ?2-agonists.

Abstract: Disclosed are novel polymorphisms in the human cytochrome P450 2A6 gene and the use of those polymorphisms as predictive sequences for altered metabolism or occurrence of disease.

Abstract: A method for predicting an individual's response to the &bgr;-agonists salmeterol, albuterol, metaproterenol, terbutaline and formoterol is disclosed. Individuals expressing the Ile164 &bgr;2AR variant are likely to exhibit a reduced response as compared to individuals expressing the Thr164 &bgr;2AR variant. The method is useful for making treatment decisions for patients suffering from asthma and chronic obstructive pulmonary diseases.

Abstract: Novel genetic variants of the Tumor Necrosis Factor Receptor Superfamily, Member 1A (TNFRSF1A) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the TNFRSF1A gene. Compositions and methods for haplotyping and/or genotyping the TNFRSF1A gene in an individual are also disclosed. Polynucleotides defined by the haplotypes disclosed herein are also described.

Abstract: Genotypes and haplotypes for thirteen polymorphic sites in the &bgr;2-adrenergic receptor (&bgr;2AR) gene are disclosed. Compositions and methods for predicting genetic predisposition to disease associated with polymorphic sites in the (&bgr;2AR) gene, as well as for predicting response to &bgr;-agonists, are also disclosed.

Abstract: Novel genetic variants of the Angiotensin Receptor 1 (AGTR1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the AGTR1 gene. Compositions and methods for haplotyping and/or genotyping the AGTR1 gene in an individual are also disclosed. Polynucleotides defined by the sequence of the haplotypes disclosed herein are also described.

Abstract: Novel genetic variants of the Angiotensin Receptor 1 (AGTR1) gene are described. Various genotypes, haplotypes, and haplotype pairs that exist in the general United States population are disclosed for the AGTR1 gene. Compositions and methods for haplotyping and/or genotyping the AGTR1 gene in an individual are also disclosed. Polynucleotides defined by the sequence of the haplotypes disclosed herein are also described.

Abstract: Methods for reducing degradation of polymerase extension products in the presence of formamide, where the polymerase extension products comprise a nonradioactive detection moiety, are disclosed. The methods comprise adding a base, a buffer or a reducing agent to the polymerase extension products. Sequencing methods which generate polymerase extension products comprising a nonradioactive detection moiety are also disclosed, wherein the degradation of the extension products is reduced or eliminated by the addition of a base, a buffer, or a reducing agent. Compositions for reducing degradation of the above polymerase extension products are also disclosed, where the compositions comprise a base, a buffer, or a reducing agent. Kits for performing sequencing methods are also disclosed, wherein the degradation of polymerase extension products is reduced or eliminated. The kits comprise a base, a buffer, or a reducing agent, and instructions.

Abstract: The present invention relates to the development of collections of a single gene locus from a collection of individuals or organisms, called genome anthologies. The invention describes several novel methods for producing collections of a gene or gene families from multiple individuals or organisms. One method is targeted in vivo cloning. Another method is locus specific primer extension and exonuclease degradation method.